Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
Small Molecule Xanthine Oxidase Inhibitors and Methods of Use
US2015005389A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2015005389-A1 |
| Application number | US-201414483085-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 10, 2014 |
| Priority date | Dec 7, 2012 |
| Publication date | Jan 1, 2015 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
First claim
Opening claim text (preview).
1 - 15 . (canceled) 16 . A method for treating a condition mediated at least in part by xanthine oxidase, wherein the method comprises administering to a patient suffering from such a condition a therapeutically effective amount of a compound comprising: or a pharmaceutically acceptable salt thereof, wherein: R 1 , R 2 , R 3 , R 4 , and R 5 are each independently selected from hydrogen, hydroxyl, cyano, fluoro, chloro, bromo, trifluoromethyl, sulfonyl, and aldehyde, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are not simultaneously hydrogen. 17 . The method of claim 16 , wherein the compound is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 18 . The method of claim 16 , wherein the compound is administered orally.
Assignees
Inventors
Classifications
Benzaldehyde · CPC title
- A61K31/11Primary
Aldehydes · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
- C07C205/44Primary
the carbon skeleton being further substituted by —CHO groups · CPC title
Diformyl benzenes; Alkylated derivatives thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2015005389A1 cover?
- Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
- Who is the assignee on this patent?
- Baylor College Medicine
- What technology area does this patent fall under?
- Primary CPC classification A61K31/11. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jan 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).